Subcutaneous Teriparatide for Pelvic Fracture Healing: A Phase 2 Randomized Controlled Trial
Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.Osteoporos Int. 2022 Jan;33(1): 239-250.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Thirty-five patients over the age of 50 with an acute pelvic fracture were randomized to receive 3 months of subcutaneous teriparatide injections (n=18) or placebo injections (n=17). Outcomes of interest included pain scores on a Numeric Rating Scale (NRS), physical performance scores (Continuous Summary Physical Performance Score [CSPPS]; timed up and go), and bone healing. Results revealed no si...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue